Immunologic Factor
sargramostim Audio
[ sar-gra-moh-stim ]
Brand Names:
Leukine
Effect:
Increased Cytokine Production
May Treat:
Breast Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma
More Information:
ChemID; DrugBank; DailyMed; DrugInfo; PDR
Definitions related to sargramostim:
  • A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.
    NCI Thesaurus
    U.S. National Cancer Institute, 2021
  • A substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets. It is a cytokine that is a type of hematopoietic (blood-forming) agent.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.